KMDA vs PHAT: stock comparison and AI forecast
Kamada Ltd (KMDA) and Phathom Pharmaceuticals, Inc. (PHAT) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
KMDA Kamada Ltd
- Market Cap
- $418M
- P/E Ratio
- 11.3x
- Size
- small-cap
- AI Forecast
PHAT Phathom Pharmaceuticals, Inc.
- Price
- $5.08 -59.9% · 6M
- Market Cap
- $413M
- P/E Ratio
- –
- Size
- small-cap
- AI Forecast
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Key facts
- KMDA and PHAT have similar market capitalizations ($418M and $413M).
- Both companies share the SEC industry classification Pharmaceutical Preparations.
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | KMDA | PHAT |
|---|---|---|
| Market Cap | $418M | $413M |
| P/E Ratio | 11.33x | – |
| EPS | $0.64 | $-0.42 |
| Revenue/Share | $5.48 | $3.38 |
| FCF/Share | – | $-0.26 |
Profitability & Margins
| Metric | KMDA | PHAT |
|---|---|---|
| ROE | 11.6% | – |
| ROA | 8.2% | – |
| ROIC | – | -15.0% |
| Gross Margin | 43.0% | 80.7% |
| Operating Margin | 15.5% | -9.3% |
| Net Margin | 9.8% | – |
| EBT Margin | 13.3% | -31.6% |
| Tax Rate | 12.7% | – |
Financial Health
| Metric | KMDA | PHAT |
|---|---|---|
| Current Ratio | – | 1.76x |
| Quick Ratio | – | 1.72x |
| Financial Leverage | 1.41x | – |
| Interest Coverage | – | -0.0x |
| Working Capital | – | $133M |
Cash Flow
| Metric | KMDA | PHAT |
|---|---|---|
| Operating Cash Flow | $43M | -$21M |
| Free Cash Flow | – | -$21M |
| Capital Spending | – | -$300K |
| OCF Growth YoY | -48.2% | – |
| FCF/Sales | – | -7.7% |
| CapEx/Sales | – | 0.1% |
Operational Efficiency
| Metric | KMDA | PHAT |
|---|---|---|
| Asset Turnover | 0.84x | 0.80x |
| Receivables Turnover | – | 2.5x |
| Inventory Turnover | 2.1x | 7.0x |
| Fixed Assets Turnover | 7.6x | 294.0x |
| Days Sales Outstanding | – | 143 days |
| Days Inventory | 172 days | 52 days |
| Payables Period | 47 days | 76 days |
| Cash Conversion Cycle | – | 119 days |
Income Statement
| Metric | KMDA | PHAT |
|---|---|---|
| Total Revenue | $316M | $275M |
| Operating Income | $49M | -$25M |
| Net Income | $31M | – |
| R&D Expense | $23M | $32M |
| SG&A Expense | – | $215M |
| Cost of Goods Sold | $180M | $53M |
Dividend & Shareholder Information
| Metric | KMDA | PHAT |
|---|---|---|
| Shares Outstanding | 58M | 81M |
| EPS Growth | 45.5% | – |
KMDA vs PHAT: stock comparison and AI forecast
Which is bigger, KMDA or PHAT?
KMDA and PHAT have similar market capitalizations ($418M and $413M).
Which one does Intratio's AI model rank higher, KMDA or PHAT?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.